Topo
O site do Hospital Beatriz Ângelo usa cookies para assegurar uma experiência de utilização adequada e para conhecer o fluxo de visitas e suas características.
Ao navegar neste site está a consentir a utilização de cookies. Para mais informações consulte a Política de Cookies.
Serviço Nacional de Saúde

Hospital Beatriz Ângelo

Navegação Principal do site

Ensaios clínicos em recrutamento



Ensaios clínicos na área do carcinoma mama
  • GO29505: A phase II randomized, double-blind study of ipatasertib (GDC-0068), an inhibitor to Akt in combination with paclitaxel as neoadjuvant treatment for patients with early stage triple negative breast cancer.
Mais informações em:
https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003029-16/PT
 
  • OLYMPIA: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy. 
Mais informações em:
https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003839-30/PT

 
Ensaios clínicos na área da colite ulcerosa
  • EVOLUTION: An open label, single group assignment design study to correlate soluble ST2 with clinical, endoscopic and histological activity in moderate to severe Ulcerative Colitis patients under golimumab.
Mais informações em:
https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003262-25/PT
 
Ensaios clínicos na área da nefrologia/endocrinologia:

    • FIDELIO: A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.

    • FIGARO: A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care. 


    Ensaios clínicos na área da pneumologia:
    • GARDENIA: Phase III, Randomized, Multicenter Double Blind, Double Dummy Study to evaluate the efficacy and safety of Etrolizumab compared with infliximab in patients with moderate to severe active ulcerative colitis who are naive to TNF inhibitors. 

    • TRIGGER: A 52 week, randomized, double blind, multinational, multicentre, active controlled, 3-arm parallel group trial comparing CHF 5993 200/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) to CHF 1535 200/6 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) alone or on top of open-label tiotropium 2.5 µg Respimat® in patients with asthma uncontrolled on high doses of inhaled corticosteroids in combination with long-acting ß2-agonists. 
    Mais informações em: 
    https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000717-40/PT

    Ensaios clínicos na área da neurologia:
    • 221AD301: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease
         Mais informação em: 

    • BI 12897: A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared to donepezil and placebo in patients with cognitive impairment due to Alzheimer's Disease
         Mais informação em: 
    • RESPECT ESUS: Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of Undetermined Source
    Mais informação em:
    https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003444-24/PT

    • BN29552: A phase III, multicenter, randomized, double- blind, placebo-controlled, parallel-group, efficacy and safety study of crenezumab in patients with prodomal-to-mild alzheimer’s disease 



    Ensaios clínicos na área do carcinoma da bexiga:
      • Danube: A Phase III, Randomized, Open-label, Controlled, Multi Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer


      Ensaios clínicos na área do carcinoma da pulmão:
        • GO29438: A phase III, open-label, randomized studyof atezolizumab (mpdl3280a, anti−pd-l1 antibody) in combination with carboplatin or cisplatin+pemetrexe compared with carboplatin or cisplatin+pemetrexed in patients who are chemotherapy-naive and have stage iv non-squamous non−small cell lung cancer.


        voltar
         
         
        Luz Saúde, S.A., Sociedade Aberta © 2017